Study S001966

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00676338
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 820
Start: 2008-11
Primary completion: 2010-07
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:exenatide once weekly; DRUG:metformin; DRUG:sitagliptin; DRUG:pioglitazone
Results posted: TRUE

Registered primary outcomes

Change in HbA1c From Baseline to Week 26 [Baseline, Week 26]
Percentage of Patients Achieving HbA1c <=7% at Week 26 [Baseline, Week 26]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013562	Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Guja C, Diabetes therapy : research, treatment and education of diabetes and related disorders	2020	Other trial	PMID 32306296 DOI	cites ClinicalTrials.gov:NCT00676338; registry reference DERIVED:32306296
R0019490	Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Grimm M, Postgraduate medicine	2013	Randomized trial	PMID 23748506 DOI	cites ClinicalTrials.gov:NCT00676338; registry reference DERIVED:23748506
R0024240	Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Meloni AR, Cardiovascular diabetology	2013	Randomized trial	PMID 23522121 DOI	cites ClinicalTrials.gov:NCT00676338; registry reference DERIVED:23522121
R0025752	Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. Malloy J, Postgraduate medicine	2013	Randomized trial	PMID 23748507 DOI	cites ClinicalTrials.gov:NCT00676338; registry reference DERIVED:23748507
R0027761	Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Russell-Jones D, Diabetes care	2012	Randomized trial	PMID 22210563 DOI	cites ClinicalTrials.gov:NCT00676338; registry reference DERIVED:22210563